Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Acrux Limited ( (AU:ACR) ) has issued an update.
Michael Kotsanis, the CEO of Acrux Limited, has announced his retirement after a significant tenure, during which he successfully developed the company’s generic drug strategy. This strategy has led to the generation of a diverse product suite, and recent capital raising efforts aim to expand the product portfolio with further FDA filings. The Board has initiated a search for a new CEO to lead the next phase of Acrux’s development and growth.
More about Acrux Limited
Acrux is a specialty pharmaceutical company with 25 years of experience in developing and commercializing topically applied pharmaceutical products. The company has successfully marketed various products worldwide, with a primary focus on the United States, and is engaged in formulating and developing a range of topical generic products.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.81M
For detailed information about ACR stock, go to TipRanks’ Stock Analysis page.
